Skip to main content

Advertisement

Table 2 Active clinical trials combining radiation with PD-1/PD-L1 targeted therapy

From: Current clinical trials testing the combination of immunotherapy with radiotherapy

NCT Number Phase Title Conditions RT Details Enrollment Sponsor/Collaborators
NCT02642809 Phase 0 Pembrolizumab With Locally Delivered Radiation Therapy for the Initial Treatment of Metastatic Esophageal Cancers Esophageal Cancer Hypofx brachytherapy 15 Washington University School of Medicine|Merck Sharp & Dohme Corp.
NCT02463994 Phase 0 A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC NSCLC Hypofx RT 12 University of Michigan Cancer Center|University of Washington
NCT02587455 Phase 1 Pembrolizumab and Palliative Radiotherapy in Lung Thoracic Tumours Palliative EBRT 48 Royal Marsden NHS Foundation Trust|Merck Sharp & Dohme Corp.
NCT02608385 Phase 1 Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors NSCLC SBRT, 3-5 fx 138 University of Chicago
NCT02621398 Phase 1 Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB NSCLC NSCLC EBRT 30 Rutgers, The State University of New Jersey|National Cancer Institute (NCI)|Merck Sharp & Dohme Corp.
NCT02313272 Phase 1 Phase I Trial of Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas Malignant Glioma FSRT over 5 days 32 H. Lee Moffitt Cancer Center and Research Institute|Merck Sharp & Dohme Corp.
NCT02402920 Phase 1 Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer Lung Cancer EBRT, 1.5 Gy × 30 fx, BID 80 M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.
NCT02716948 Phase 1 Stereotactic Radiosurgery and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine Melanoma (Brain metastases) SRS 90 Sidney Kimmel Comprehensive Cancer Center
NCT02560636 Phase 1 Pembrolizumab in Muscle Invasive/Metastatic Bladder Cancer Invasive Bladder Cancer Hypofx RT 34 Royal Marsden NHS Foundation Trust|Merck Sharp & Dohme Corp.
NCT02318771 Phase 1 Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer Metastatic HN, RCC, Melanoma, Lung Cancer EBRT 40 Thomas Jefferson University|Merck Sharp & Dohme Corp.
NCT02648633 Phase 1 Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma Glioblastoma SRS 17 University of Virginia
NCT02303366 Phase 1 Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475 Oligometastatic Breast Cancer SBRT, 20 Gy × 1 fx 15 Peter MacCallum Cancer Centre, Australia
NCT02659540 Phase 1 A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma Melanoma 3 Gy × 10 fx, or 9 Gy × 3 fx 18 Ludwig Institute for Cancer Research|Bristol-Myers Squibb
NCT02586207 Phase 1 Pembrolizumab in Combination With CRT for LA-SCCHN Advanced HN Cancers EBRT, 7 wks 39 Sanford Health|Merck Sharp & Dohme Corp.
NCT02303990 Phase 1 RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers Metastatic Cancers Hypofx RT 70 Abramson Cancer Center of the University of Pennsylvania
NCT02764593 Phase 1 Chemotherapy +/- Nivolumab in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma Advanced HN Cancers IMRT, 7 wks 120 RTOG Foundation, Inc.|Bristol-Myers Squibb
NCT02400814 Phase 1 MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With NSCLC NSCLC SBRT, 5 fx 45 University of California, Davis|National Cancer Institute (NCI)|Genentech, Inc.
NCT02383212 Phase 1 Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies Advanced Cancer Hypofx RT 973 Regeneron Pharmaceuticals|Sanofi
NCT02311361 Phase 1 Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer Pancreatic Cancer SBRT, 1-5 fx 60 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
NCT02696993 Phase 1|Phase 2 Phase I/II Trial of Nivolumab With Radiation or Nivolumab and Ipilimumab With Radiation for the Treatment of Intracranial Metastases From NSCLC Lung Cancer (Brain metastases) WBRT 3 Gy × 10 fx, SRS 1 fx 80 M.D. Anderson Cancer Center|Bristol-Myers Squibb
NCT02444741 Phase 1|Phase 2 MK-3475 and Hypofractionated Stereotactic Radiation Therapy in Patients With NSCLC (NSCLC) Lung Cancer EBRT or SBRT 104 M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.
NCT02530502 Phase 1|Phase 2 Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma Glioblastoma EBRT 50 Northwestern University|Merck Sharp & Dohme Corp.|National Cancer Institute (NCI)
NCT02730546 Phase 1|Phase 2 Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery Gastric Cancer EBRT 68 Mayo Clinic|National Cancer Institute (NCI)
NCT02759575 Phase 1|Phase 2 A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma Advanced HN Cancers EBRT 47 Nooshin Hashemi-Sadraei|Merck Sharp & Dohme Corp.|University of Cincinnati
NCT02407171 Phase 1|Phase 2 Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC Melanoma, Lung Cancer SBRT, 1-5 fx 60 Yale University
NCT02735239 Phase 1|Phase 2 Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer Esophageal Cancer EBRT 75 Ludwig Institute for Cancer Research|AstraZeneca
NCT02305186 Phase 1|Phase 2 Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer Pancreatic Cancer EBRT, 1.8 Gy × 28 fx 56 Osama Rahma, MD|M.D. Anderson Cancer Center|University of Virginia
NCT02599779 Phase 2 A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients Metastatic RCC SBRT 35 Sunnybrook Health Sciences Centre|Merck Sharp & Dohme Corp.|Ozmosis Research Inc.
NCT02648282 Phase 2 Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer Pancreatic Cancer SBRT, 3-5 fx 54 Sidney Kimmel Comprehensive Cancer Center|Merck Sharp & Dohme Corp.
NCT02492568 Phase 2 Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLC NSCLC SBRT, 8 Gy × 3 fx 74 The Netherlands Cancer Institute|Merck Sharp & Dohme Corp.
NCT02641093 Phase 2 Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma HN Cancer EBRT, 6 wks 80 Trisha Wise-Draper|Merck Sharp & Dohme Corp.|University of Cincinnati
NCT02684253 Phase 2 Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) HN Cancer SBRT, 9 Gy x 3 fx 40 Memorial Sloan Kettering Cancer Center|University of Chicago
NCT02667587 Phase 2 Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer). Glioblastoma EBRT 320 Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
NCT02437071 Phase 2 Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients Metastatic Colorectal Cancer EBRT vs radiofrequency ablation 48 Memorial Sloan Kettering Cancer Center|Merck Sharp & Dohme Corp.
NCT02658097 Phase 2 A Randomized Two Arm Phase II Trial of Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC Stage IV NSCLC 8 Gy × 1 fx 66 Case Comprehensive Cancer Center
NCT02562625 Phase 2 Trial of Pembrolizumab and Radiotherapy in Melanoma Melanoma 8 Gy × 3 fx 234 Royal Marsden NHS Foundation Trust|University of Manchester|University of Leeds
NCT02730130 Phase 2 Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients Metastatic Breast Cancer EBRT 17 Memorial Sloan Kettering Cancer Center|Merck Sharp & Dohme Corp.
NCT02707588 Phase 2 Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC Advanced HN Cancers EBRT 114 Groupe Oncologie Radiotherapie Tete et Cou
NCT02621151 Phase 2 Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder Muscle-invasive Urothelial Cancer of the Bladder Hypofx RT 54 New York University School of Medicine|Merck Sharp & Dohme Corp.
NCT02609503 Phase 2 Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin Head and Neck Cancer IMRT, 7 wks 29 UNC Lineberger Comprehensive Cancer Center|Merck Sharp & Dohme Corp.
NCT02677155 Phase 2 Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma Follicular Lymphoma 8 Gy × 1 fx 20 Oslo University Hospital|Norwegian Cancer Society|Merck Sharp & Dohme Corp.
NCT02586610 Phase 2 Trial of Chemoradiation and Pembrolizumab in Patients With Rectal Cancer Rectal Cancer EBRT, 1.8 Gy × 28 fx 53 Osama Rahma, MD|Hoosier Cancer Research Network|Merck Sharp & Dohme Corp.
NCT02434081 Phase 2 NIvolumab COnsolidation After Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B NSCLC NSCLC EBRT 43 European Thoracic Oncology Platform|Bristol-Myers Squibb|Frontier Science Foundation, Hellas
NCT02296684 Phase 2 Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma HN Cancer IMRT, 6 wks 46 Washington University School of Medicine|Merck Sharp & Dohme Corp.
NCT02499367 Phase 2 Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients Breast Cancer 20 Gy × 1, or 8 Gy × 3 84 The Netherlands Cancer Institute|Bristol-Myers Squibb
NCT02635360 Phase 2 Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer Cervical Cancer EBRT + brachytherapy 88 Linda R Duska|Merck Sharp & Dohme Corp.|University of Virginia
NCT02662062 Phase 2 Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer Bladder Cancer EBRT, 6 wks 30 Australian and New Zealand Urogenital and Prostate Cancer Trials Group
NCT02336165 Phase 2 Phase 2 Study of MEDI4736 in Patients With Glioblastoma Glioblastoma EBRT 108 Ludwig Institute for Cancer Research|MedImmune LLC
NCT02289209 Phase 2 Reirradiation With MK-3475 (Pembrolizumab) in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck Recurrent HN Cancers EBRT 48 Dan Zandberg|Merck Sharp & Dohme Corp.|University of Maryland
NCT02768558 Phase 3 Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC NSCLC EBRT (IMRT or 3D CRT) 660 RTOG Foundation, Inc.|Bristol-Myers Squibb
NCT02617589 Phase 3 Study of Nivolumab Versus Temozolomide, Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) Brain Cancer EBRT 550 Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd
  1. Abbreviations: 3D CRT 3-dimensional conformal radiation therapy, EBRT external beam radiation in conventional fractions, fx fractions, hypofx hypofractionated, IMRT intensity modulated radiation therapy, FSRT fractionated stereotactic radiation, HN head and neck, SBRT stereotactic body radiation therapy, SRS stereotactic radiosurgery